Home › Compare › ALVLF vs ABBV
ALVLF yields 714.29% · ABBV yields 3.06%● Live data
📍 ALVLF pulled ahead of the other in Year 1
Combined, ALVLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALVLF + ABBV for your $10,000?
Big Ridge Gold Corp. owns and operates gold exploration projects in Canada. The company's principal project is the Hope Brook Gold project that includes 1,056 mineral claims totaling 26,400 hectares located in Newfoundland. It also holds 100% interests in the Oxford Gold project that includes 17 contiguous mineral claims and three mineral exploration licenses, which cover approximately 35,992 hectares located in Manitoba; and the Destiny Gold project that comprises 127 mineral claims totaling 5,013 hectares located in Quebec. In addition, the company owns 100% interests in the Beardmore-Geraldton gold belt that includes 15 mineral leases totaling 409 hectares in Ontario. The company was formerly known as Alto Ventures Ltd. and changed its name to Big Ridge Gold Corp. in September 2020. Big Ridge Gold Corp. was incorporated in 1987 and is headquartered in Toronto, Canada.
Full ALVLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.